The use of whole exome sequencing and murine patient derived xenografts as a method of chemosensitivity testing in sarcoma

Table 2 Sequencing metrics

Diagnosis	Depth	Reads (M)	% on-target reads	Somatic mutations	Synonymous	Non-synonymous	INDEL	Frame-shift	Stop gain/loss
Osteosarcoma
Germline	88.1	75	89.1
Tumour	153.2	134	81.5	479	144	290	12	24	9
PDX	282.7	141	53.9	96,393	79,080	15,354	440	1334	139
Dedifferentiated liposarcoma
Germline	74.7	71	89.8
Tumour	148.5	123	79.4	458	154	250	14	28	12
Leiomyosarcoma
Germline	94.9	778	79.0
Tumour	145.7	116	81.1	384	118	218	15	26	7
Osteosarcoma
Germline	72.1	613	74.7
Tumour	175.2	148	79.0	575	179	331	18	30	17
PDX	142.1	123	80.2	288,522	232,825	48,320	1496	5307	477
Synovial sarcoma
Germline	71.5	784	58.3
Tumour	159.6	134	79.5	471	169	245	13	32	12
Ewing’s sarcoma
Germline	65.8	730	58.4
Tumour	122.7	128	61.0	529	191	262	21	45	10
PDX	141.7	125	75.5	7089	3399	3416	115	105	53
Undifferentiated pleomorphic sarcoma
Germline	77.1	677	75.4
Tumour	139.6	132	72.5	522	202	271	15	26	7
PDX	168	137	79.4	118,641	97,602	18,574	568	1651	207
Alveolar rhabdo-myosarcoma
Germline	83.1	727	86.6
Tumour	152.6	132	86.3	591	187	325	25	39	12
PDX	187.3	159	76.7	24,851	12,266	10,617	121	331	117
Leiomyosarcoma
Germline	98.8	880	76.7
Tumour	166	147	80.2	368	112	220	5	20	11
PDX	159.8	134	77.9	34,442	28,019	5701	183	470	67
Chordoma
Germline	70.7	617	77.5
Tumour	145.8	141	78.9	440	147	247	7	31	8
Metastatic angiosarcoma
Germline	72	632	76.1
Tumour	202.2	176	78.2	489	177	249	17	36	10
PDX	147	121	77.7	10,376	7892	2238	42	148	52
Undifferentiated pleomorphic sarcoma
Germline	78.6	692	82.4
Tumour	146	119	82.6	405	147	210	16	25	7

ISSN: 2045-3329